← 產業報告目錄
CD47 Targeting Therapeutics Market Size, Share & Trends Analysis Report By Target disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Other Diseases Indications), By Type of Molecule, By Region, And By Segment Forecasts, 2028-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-27頁數 180報告編號 INSIGHTACE-bb9b545bd3
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2028 to 2034 projection horizon, the worldwide CD47 Targeting Therapeutics Market is anticipated to register a CAGR of 35%.
The CD47 Targeting Therapeutics sector involves key industry insights & findings from the report:
The factors driving the growth of the cd47 targeting therapeutics market include the rising developments in the cd47-targeting anti-cancer therapies . This domain has witnessed meaningful transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is underpinned by expanding healthcare spending, technological evolution, and the expanding focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CD47 Targeting Therapeutics Market Snapshot
Chapter 4. Global CD47 Targeting Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 2: By Target Disease Indication Estimates & Trend Analysis
5.1. By Target Disease Indication & Market Share, 2028 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Target Disease Indication:
5.2.1. Acute Myeloid Leukemia
5.2.2. Non-Hodgkin Lymphoma
5.2.3. Colorectal Cancer
5.2.4. Diffuse Large B-cell Lymphoma
5.2.5. Myelodysplastic Syndromes
5.2.6. Non-Small Cell Lung Cancers
5.2.7. Ovarian Epithelial Cancer
5.2.8. Oral Muscositis
5.2.9. Small Cell Lung Cancers
Chapter 6. Market Segmentation 4: By Molecules Estimates & Trend Analysis
6.1. By Molecules & Market Share, 2028 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Molecules:
6.2.1. Biologics
6.2.2. Small Molecule
Chapter 7. CD47 Targeting Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Target Disease Indication, 2021-2034
7.1.2. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Types, 2021-2034
7.1.3. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.1.4. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.2.2. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.2.3. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.2.4. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.3.2. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.3.3. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.3.4. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.4.2. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.4.3. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.4.4. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.5.2. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.5.3. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.5.4. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Abpro
8.2.2. ALX Oncology
8.2.3. Apmonia Therapeutics
8.2.4. Arch Oncology
8.2.5. Aurigene
8.2.6. Bristol Myers Squibb
8.2.7. Conjupro biotherapeutics
8.2.8. EpicentRx
8.2.9. Forty Seven
8.2.10. ImmuneOncia Therapeutics
8.2.11. ImmuneOnco Biopharmaceuticals
8.2.12. Innovent Biologics
8.2.13. KAHR Medical
8.2.14. Light Chain Bioscience
8.2.15. Morphiex
8.2.16. Trillium Therapeutics
8.2.17. TG Therapeutics
8.2.18. Adagene
8.2.19. Alector, Inc.
8.2.20. Apmonia Therapeutics
8.2.21. I-MAB Biopharma Co., Ltd.
8.2.22. QLSF Biotherapeutics Inc.
8.2.23. Phanes Therapeutics, Inc.
8.2.24. Bio-Thera Solutions
8.2.25. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們